Complete spontaneous regression of primary Merkel cell carcinoma with tumoural infiltration: a systematic review.

Eur J Dermatol

Service de Dermatologie, Université de Nantes, CHU Nantes, CIC 1413, CRCINA, F-44000 Nantes, France, CIC 1413, CRCINA INSERM 1232, Nantes, France.

Published: June 2021

Merkel cell carcinoma (MCC) is an aggressive tumour that rapidly evolves to metastasis, however, paradoxically, complete spontaneous regression (CSR) of MCC has been reported. CSR may be linked to the presence of Merkel cell polyomavirus (MCPyV) combined with immune response tumour-infiltrating lymphocytes (TILs). To elucidate the mechanism of CSR by studying the profile of TIL infiltration and the role of MCPyV. We describe a clinical case of CSR with MCC and provide the results of a literature review based on PubMeb and Embase databases, from January 1 1986 to April 1 2010, using the terms: "Merkel cell carcinoma" and "complete spontaneous regression". We found 38 clinical cases of CSR of primary MCC at different stages. The rate of MCPyV positivity was 75%, as found generally in MCC. The peritumoural infiltration was mostly composed by CD3+ T cells, whereas the intratumoural infiltration revealed CD8+ T cells, defined as TILs. To further investigate TILs in CSR of MCC, immunohistochemical staining was performed and compared to three non-regressive MCCs. CD8, IFNɣ and LAG3 expression was higher in biopsy samples with tumour regression, mainly inside the tumour nest. TILs were significantly more abundant in regressive MCC than in non-regressive MCC, in which both IFNɣ and LAG3 levels were low. This review and our clinical case confirms the central role of TILs in regressive MCC associated with IFNɣ and LAG3 secretion, thus underlining the interest in checkpoint inhibitors and adoptive T cell therapy in the treatment of MCC.

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2021.4065DOI Listing

Publication Analysis

Top Keywords

merkel cell
12
csr mcc
12
ifnɣ lag3
12
mcc
10
complete spontaneous
8
spontaneous regression
8
cell carcinoma
8
clinical case
8
regressive mcc
8
csr
6

Similar Publications

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

Eur J Cancer

January 2025

Melanoma Institute Australia, The University of Sydney, Wollstonecraft, Australia; Blacktown Hospital, Blacktown, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. Electronic address:

Aim: Merkel Cell Carcinoma (MCC) is a rare skin cancer with a rising incidence worldwide. Anti-programmed death-1/ligand-1 (anti-PD-(L)1) therapies are effective for the treatment of advanced MCC. This study examines patterns of response / progression of advanced MCC to anti-PD-(L)1 therapies and describes subsequent management.

View Article and Find Full Text PDF

Surgical Outcomes for Nonmelanoma Skin Cancer of the Head and Neck.

Ann Plast Surg

January 2025

Department of Plastic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan Province, China.

Objectives: There is no consensus on elective lymphatic dissection of the parotid and neck for nonmelanoma skin cancer (NMSC) due to challenges in detecting occult spread to these regions. This study aimed to summarize clinical data and evaluate correlations between risk factors, nodular metastasis, and the need for elective parotidectomy in patients with cutaneous squamous cell carcinoma (CSCC), Merkel cell carcinoma (MCC), and apocrine carcinoma (AC) of the head and neck, all with clear surgical margins and negative imaging results for regional metastases.

Study Design: We retrospectively reviewed 166 patients with CSCC, one with MCC, and one with AC of the head and neck, all treated surgically between September 2006 and July 2022.

View Article and Find Full Text PDF

Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.

View Article and Find Full Text PDF

Background: Patients with haematologic malignancies are at increased risk of developing skin cancer and often experience worse skin cancer-related outcomes. However, there is a lack of nationwide, population-based data with long-term follow-up on the incidence and risks of different skin cancer types across all haematologic malignancies.

Objectives: To assess population-based risk estimates for cutaneous squamous cell carcinoma (CSCC), malignant melanoma (MM), Merkel cell carcinoma (MCC), and basal cell carcinoma (BCC) among patients with haematologic malignancies, stratified by skin cancer type and haematologic malignancy subgroup.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!